Clinical Trial Update: Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial CM310 in pediatric patients with moderate-to-severe atopic dermatitis has completed; the study was conducted by Keymed Biosciences Co.Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CM310

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED